The group’s principle activity is to develop automated microarray based multiplexing molecular diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious diseases, cancer and pharmacogenetics. The group operates from United States.
